Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
NeoGenomics operates specialized cancer-focused testing laboratories providing molecular and genetic diagnostic services to pathologists, oncologists, and hospitals across the United States and internationally. The company processes approximately 500,000+ tests annually through its CLIA-certified labs, specializing in complex oncology diagnostics including next-generation sequencing, flow cytometry, and immunohistochemistry. Trading at 0.4x sales with negative margins, the stock reflects operational restructuring challenges following aggressive expansion, with recent 64% six-month rally suggesting investor anticipation of margin recovery.
NeoGenomics generates revenue through fee-for-service diagnostic testing with reimbursement from Medicare (approximately 40-45% of clinical revenue), commercial insurance (35-40%), and client billing. Pricing power derives from specialized oncology expertise and proprietary test panels that command premium reimbursement rates versus routine pathology. The pharma services segment operates on contracted project basis with higher margins (estimated 50-60% gross margins) versus clinical testing (40-45% gross margins). Competitive advantages include comprehensive oncology test menu (600+ tests), established payer relationships with contracted rates, and CAP/CLIA accreditations required for complex molecular diagnostics. However, the company faces reimbursement pressure from Medicare rate cuts and prior authorization requirements implemented in recent years.
Clinical test volume trends and requisition growth rates, particularly advanced molecular testing (NGS panels, liquid biopsy) which drive higher revenue per requisition
Medicare reimbursement policy changes and CMS rate updates for molecular diagnostic codes (81455, 81479, 0245U series)
Pharma services contract wins and clinical trial activity levels in oncology drug development pipeline
Operating margin trajectory and progress toward breakeven EBITDA, including cost reduction execution and lab consolidation milestones
Competitive dynamics with larger reference labs (Quest, LabCorp) expanding oncology capabilities and specialized competitors (Guardant, Foundation Medicine) in liquid biopsy
Medicare reimbursement rate cuts and policy changes including MolDX program restrictions on molecular diagnostic coverage, with CMS historically reducing rates 5-10% every few years for established test codes
Technology disruption from AI-powered diagnostic platforms and liquid biopsy competitors (Guardant360, FoundationOne Liquid) potentially commoditizing traditional tissue-based testing
Regulatory risk from FDA oversight expansion into laboratory-developed tests (LDTs), requiring costly clinical validation studies and premarket approval for proprietary assays
Market share erosion as Quest Diagnostics and LabCorp leverage scale advantages and integrated physician networks to expand oncology testing capabilities at lower cost structures
Pricing pressure from hospital in-sourcing of molecular testing as NGS equipment costs decline and academic medical centers build internal precision oncology programs
Specialized competitors with superior technology in high-growth segments: Guardant/Natera in liquid biopsy, Foundation Medicine in comprehensive genomic profiling with pharma partnerships
Negative free cash flow ($-0.0B TTM, -8.2% FCF yield) creates liquidity risk if operational turnaround delays, though $150M+ cash balance and 4.26 current ratio provide 12-18 month runway at current burn rate
Goodwill and intangible assets from historical acquisitions (estimated $200-300M) face potential impairment charges if revenue recovery stalls, further pressuring book value already at 0.3x price/book
Debt covenant compliance risk if EBITDA remains negative beyond 2026, potentially triggering refinancing requirements or restrictive amendments
moderate - Cancer diagnostics demonstrate relative recession resilience as testing is medically necessary and largely reimbursed by insurance/Medicare rather than out-of-pocket. However, economic downturns impact elective procedures and cancer screening rates (colonoscopies, mammograms) which drive downstream diagnostic testing demand. The pharma services segment shows higher cyclicality tied to biotech funding environment and clinical trial spending. Healthcare employment levels and insurance coverage rates also influence testing volumes, with uninsured/underinsured patients delaying care during economic stress.
Rising rates create moderate headwinds through two channels: (1) Higher cost of capital for growth investments and potential refinancing of $150M+ debt load, though current 0.49 debt/equity ratio is manageable; (2) Valuation multiple compression as healthcare growth stocks typically trade on forward EV/Revenue multiples that contract when risk-free rates rise. The company's path to profitability becomes more critical in higher-rate environment as investors demand faster cash flow generation. Conversely, rate cuts would ease financing costs and potentially expand valuation multiples for unprofitable growth healthcare names.
Moderate exposure through two mechanisms: (1) Reimbursement risk as commercial payers tighten prior authorization and coverage policies during economic stress, extending collection cycles and increasing bad debt; (2) Pharma services revenue dependent on biotech/pharmaceutical R&D spending, which contracts when venture capital and IPO markets freeze during credit tightening. The company's 4.26 current ratio provides liquidity buffer, but negative operating cash flow makes it vulnerable to prolonged credit market disruption affecting healthcare reimbursement or pharma funding.
value/turnaround - The 0.4x price/sales and 0.3x price/book valuation attracts deep value investors betting on operational restructuring and margin recovery. Recent 64% six-month rally suggests momentum traders entering on technical breakout. The stock appeals to healthcare specialists focused on diagnostic sector consolidation opportunities and distressed healthcare growth names trading below tangible book value. Not suitable for income investors (no dividend) or risk-averse growth investors given negative profitability and execution risk. Requires 18-24 month investment horizon for turnaround thesis to materialize.
high - Small-cap healthcare stock ($0.3B market cap) with negative earnings exhibits elevated volatility driven by quarterly earnings surprises, reimbursement policy announcements, and sector rotation. The -17.3% one-year return followed by 64% six-month rally demonstrates boom-bust price action typical of turnaround situations. Estimated beta above 1.5x given healthcare growth stock characteristics and operational leverage to volume inflection. Options market likely prices elevated implied volatility around earnings events and CMS policy announcements.
